| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 311,60 | 312,20 | 19:59 | |
| 311,35 | 312,55 | 19:59 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 349,00 | 10 | |||
| 338,10 | 1 | |||
| 326,00 | 4 | |||
| 325,00 | 100 | |||
| 310,95 | 26 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 26 | 310,30 | |||
| 10 | 300,10 | |||
| 4 | 260,00 | |||
| 1.043 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.083 | 0,130 | 141 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:48:50 | 310,60 | 14 |
| 16:34:46 | 309,25 | 1 |
| 15:42:03 | 309,05 | 51 |
| 15:42:03 | 308,90 | 40 |
| 11:15:10 | 310,05 | 2 |
| 11:15:10 | 310,30 | 29 |
| 11:15:10 | 310,30 | 1 |
| 11:15:10 | 310,40 | 29 |
| 11:15:10 | 310,40 | 1 |
| 11:15:10 | 310,45 | 40 |
| Tagesumsatz Xetra | -1,50 -0,48 % | 220 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:06 | EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA FOR GENERALIZED MYASTHENIA GRAVIS | 397 | PR Newswire | First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMGUPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing*THOUSAND OAKS, Calif.... ► Artikel lesen | |
| AMGEN Aktie jetzt für 0€ handeln | |||||
| Fr | $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today | 21 | Benzinga.com | ||
| Fr | P/E Ratio Insights for Amgen | 19 | Benzinga.com | ||
| Fr | CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder | 8 | Benzinga.com | ||
| Fr | Starke Quartalszahlen: Guggenheim hebt Amgen-Kursziel auf 347 Dollar an | 23 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 16:15 | PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR | Dow Jones News | DJ PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Vidac Pharma Holding PLC:... ► Artikel lesen | |
| 14:50 | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Newsfile | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| 12:36 | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | GlobeNewswire (Europe) | PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany... ► Artikel lesen | |
| 13:36 | Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market | Business Wire | Augments Alkermes' Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ (Sodium Oxybate) for Extended-Release Oral Suspension
Expected to be... ► Artikel lesen | |
| 14:26 | Bullion Gold Resources Corporation: Drilling Resumes at Bousquet Gold Project, Quebec | Newsfile | Montréal, Québec--(Newsfile Corp. - February 12, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or the "Company") is pleased to announce that it's partner Olympio Metals ("Olympio")... ► Artikel lesen |